Giuseppe Gerna1, Maurizio Zavattoni1, Elena Percivalle1, Paolo Grossi2, Maria Torsellini2, Maria Grazia Revello3,2
1Viral Diagnostic Service, IRCCS Policlinico San Matteo,1 and
2Institute of Infectious Diseases, University of Pavia,2 Pavia, Italy
3IRCCS Fondazione Policlinico San Matteo
Tóm tắt
ABSTRACT
In 7 of 18 solid-organ transplant recipients with primary human cytomegalovirus (HCMV) infection, HCMV antigenemia levels were unexpectedly found to rise significantly (
P
= 0.018) during a mean time of 7.3 ± 3.2 days after initiation of specific antiviral treatment, whereas corresponding levels of viremia dropped significantly (
P
= 0.043). Thus, shifting to an alternative antiviral drug based solely on increasing antigenemia levels is not justified in this group of patients.
